Form 4 for INSM INSMED Inc
Accepted 2026-04-17 16:43:36 ET · period of report 2026-04-16 · accession 0001402051-26-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-17 16:43 | 2026-04-16 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $24.94 | +10.7K | 311.9K | +4% | +$266.8K |
| DMT | 2026-04-17 16:43 | 2026-04-16 | INSM | Lewis William | COB, CEO, Dir | S - Sale+OE | $143.97 | -10.7K | 301.2K | -3% | -$1.54M |
| DMT | 2026-04-17 16:43 | 2026-04-16 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $0.00 | -10.7K | 26.6K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-16 | M | A | 6,259 | $30.46 | 307,444 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-04-16 | M | A | 4,440 | $17.16 | 311,884 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 3 | Common | Common Stock | 2026-04-16 | S | D | 2,246 | $142.99 | 309,638 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 2,246 shares sold at prices ranging from $142.39 to $143.38 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-04-16 | S | D | 5,373 | $143.81 | 304,265 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 5,373 shares sold at prices ranging from $143.39 to $144.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Common | Common Stock | 2026-04-16 | S | D | 2,255 | $144.66 | 302,010 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) This is the weighted average sales price representing 2,255 shares sold at prices ranging from $144.40 to $145.20 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Common | Common Stock | 2026-04-16 | S | D | 825 | $145.79 | 301,185 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) This is the weighted average sales price representing 825 shares sold at prices ranging from $145.53 to $146.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 7 | Derivative | Stock Option (right to buy) | 2026-04-16 | M | D | 6,259 | $0.00 | 37,555 | D | $30.46 · — to 2028-01-04 | 6,259 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F6) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 8 | Derivative | Stock Option (right to buy) | 2026-04-16 | M | D | 4,440 | $0.00 | 26,640 | D | $17.16 · — to 2027-05-17 | 4,440 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F6) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |